Company
Headquarters: Florham Park, NJ, United States
Employees: 77
CEO: Ms. Terrie J. Curran
$1.12 Billion
USD as of Jan. 1, 2026
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $158.96 B |
| Vertex Pharmaceuticals Incorporated | $115.92 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $82.28 B |
| Marinomed Biotech AG | $70.11 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
| Last Financial Reports Date | Dec. 31, 2023 |
| Revenue TTM | $682,000 |
| EBITDA | $-166,736,992 |
| Gross Profit TTM | $515,000 |
| Profit Margin | 75.51% |
| Operating Margin | -10245.60% |
| Quarterly Revenue Growth | % |
Phathom Pharmaceuticals, Inc. has the following listings and related stock indices.
Stock: NASDAQ: PHAT